Nykredit A/S’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nykredit A/S’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$427K	Buy	+7,460	New	+$409K	﹤0.01%	740

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nykredit A/S's BMRN Position: Q2 2026 in Review

Nykredit A/S opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 7,460 shares worth $427K. The stake represents ﹤0.01% of the portfolio and ranks #740 among its holdings.

416 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Nykredit A/S held 7,460 shares of BioMarin Pharmaceuticals worth $427K as of Q2 2026.
BioMarin Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #740 holding.
416 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.